Measles, Rubella, and Mumps in Mexico: A National Serosurvey Highlighting Reemergence Risks.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Salas-Lais Angel Gustavo, Fernandes-Matano Larissa, Torres-Flores Alejandro, Morales-Hernández María Luisa, López-Macías Constantino, Martínez-Miguel Bernardo, Tepale-Segura Araceli, Guerrero-García José de Jesús, Alvarado-Yaah Julio Elias, Anguiano-Hernández Yu-Mei, Castro-Escamilla Octavio, Zamudio-Chávez Óscar, Herrera-Gómez Felipe de Jesús, Krug-Llamas Ernesto, Romero-Feregrino Rodrigo, Santacruz-Tinoco Clara Esperanza, Bonifaz Laura C, Díaz-Jiménez Carlos, Vargas-García Alejandro Manuel, Muñoz-Medina José Esteban, Santos-Carrillo Alva Alejandra
Аннотация
METHODS: A retrospective, cross-sectional serological survey was conducted, including 9,587 serum samples collected from 31 of the 32 federal entities of Mexico between September and December 2024. IgG antibody levels against measles, rubella, and mumps were quantified using chemiluminescent immunoassays. Seroprevalence was analyzed by age, sex, and geographic region.
RESULTS: The overall seroprevalence rates were 78.3% for measles, 88.6% for rubella, and 81.5% for mumps (p <0.05). An age-stratified analysis revealed significant gaps in immunity against measles and mumps, particularly among those aged 10-39, where seroprevalence dropped below 70%. In contrast, more consistent protection against rubella was observed across all age groups, though younger children had lower antibody titers. Regional analysis indicated that only older adults reached the protective threshold against measles in all states.
CONCLUSIONS: This study demonstrates that the current seroprevalence in Mexico does not correspond to the vaccination coverage recommended by the WHO and highlights the urgent need to strengthen vaccination strategies, conduct catch-up campaigns, and carry out continuous seroepidemiological surveillance to maintain elimination goals.